Please assess the completion status of the following clinical trial:

Trial Title: Study of Immune Response Modifier in the Treatment of Hematologic Malignancies

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Subjects are eligible for the study if they meet all of the following~Inclusion Criteria:~* Diagnosis of one of the following hematologic malignancies not responding to at least 2 standard treatment regimens. Any criteria for persistent or recurrent disease acceptable, i.e. ≥5% blasts for acute leukemia.~  * acute lymphoblastic leukemia (ALL)~ * acute myeloid leukemia (AML)~ * non-Hodgkin's lymphoma (NHL)~ * Hodgkin's lymphoma (HL)~ * multiple myeloma (MM)~ * chronic lymphocytic leukemia (CLL)~* Performance status - Karnofsky \> 50% for patients \> 10 years of age or Lansky \>50% for patients \< 10 year of age~* Normal organ function within 14 days of study entry~* If female and of childbearing potential, are willing to use adequate contraception (hormonal, barrier method, abstinence) prior to study entry and for the duration of study participation. A female is considered to be of childbearing potential unless she has had her uterus removed, had a double oophorectomy, or has been amenorrheic for at least 6 months after chemotherapy~Exclusion Criteria:~* Had/have the following prior/concurrent therapy:~  * Systemic corticosteroids (oral or injectable) within 7 days of first dose of 852A (topical or inhaled steroids are allowed)~ * Investigational drugs/agents within 14 days of first dose of 852A~ * Immunosuppressive therapy, including cytotoxic agents within 14 days of first dose of 852A (nitrosoureas within 30 days of first dose)~ * Drugs known to induce QT interval prolongation and/or induce Torsades De Pointes unless best available drug required to treat life-threatening conditions~ * Radiotherapy within 4 weeks of the first dose of 852A~ * Hematopoietic cell transplantation 4 weeks of first dose of 852A~* Active infection or fever \> 38.5°C within 3 days of first dose of 852A~* Cardiac ischemia, cardiac arrhythmias or congestive heart failure uncontrolled by medication~* History of, or clinical evidence of, a condition which, in the opinion of the investigator, could confound the results of the study or put the subject at undue risk~* Uncontrolled intercurrent or chronic illness~* Active autoimmune disease requiring immunosuppressive therapy within 30 days~* Active hepatitis B or C with evidence of ongoing viral replication~* Hyperthyroidism~* Uncontrolled seizure disorder~* Active coagulation disorder not controlled with medication~* Pregnant or lactating~* Concurrent malignancy (if in remission, at least 5 years disease free) except for localized (in-situ) disease, basal carcinomas and cutaneous squamous cell carcinomas adequately treated~* Proven active central nervous system (CNS) disease~* Human Immunodeficiency Virus (HIV) positive~* Congenital long QT syndrome or abnormal baseline QTc interval (\> 450 msec in males and \> 470 msec in females) after Bazett's correction (QTc msec = QT msec / square root of the RR interval in seconds) on screening electrocardiogram (ECG).

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 852A Treatment (Type: EXPERIMENTAL): Patients receiving at least one dose of 852A.

Based on this trial design, predict the completion outcome and termination type (if applicable).